| 产品描述： | SR11237 (BMS-649) is a potent retinoid X receptor (RXR)-selective agonist that is devoid of any RAR activity. SR11237 can cause RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element |
| 靶点： |
RAR/RXR |
| 体外研究： |
Using nuclear receptor co-transfection assays in COS-1 cells, that SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors. |
| 体内研究： |
SR11237 (BMS-649) (25 mg/kg; i.p.; daily from post-natal days 5 to 15) causes irregular ossification and premature closure of the growth plate Animal Model: Sprague-Dawley rats Dosage: 25 mg/kg Administration: I.p.; daily from post-natal days 5 to 15 Result: Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis. |
| 参考文献： |
1. Gendimenico GJ, et al. A pleiotropic response is induced in F9 embryonal carcinoma cells and rhino mouse skin by All-trans-retinoic acid, a RAR agonist but not by SR11237, a RXR-selective agonist. J Invest Dermatol. 1994;102(5):676-680. 2. Dupuis H, et al. Exposure to the RXR Agonist SR11237 in Early Life Causes Disturbed Skeletal Morphogenesis in a Rat Model. Int J Mol Sci. 2019;20(20):5198. Published 2019 Oct 20. 3. H.L. Dupuis. The RXR agonist SR-11237 affects skeletal development. ABSTRACT ONLY| VOLUME 24, SUPPLEMENT 1, S147, APRIL 01, 2016. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.628 ml |
13.141 ml |
26.283 ml |
| 5 mM |
0.526 ml |
2.628 ml |
5.257 ml |
| 10 mM |
0.263 ml |
1.314 ml |
2.628 ml |
| 50 mM |
0.053 ml |
0.263 ml |
0.526 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京